Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-20. Numbers and descriptions here follow the published literature rather than marketing material.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
=== Infectious diseases === Among the human-specific infectious pathogens studied on humanized mice models, the human immunodeficiency virus has been successfully studied. Besides this, humanized models for studying Ebola virus, Hepatitis B, Hepatitis C, Kaposi's sarcoma-associated herpesvirus, Leishmania major, malaria, and tuberculosis have been reported by various studies. NOD/scid mice models for dengue virus and varicella-zoster virus, and a Rag2null𝛾cnull model for studying influenza virus have also been developed.
Ants communicate with each other using pheromones, sounds, and touch. Since most ants live on the ground, they use the soil surface to leave pheromone trails that may be followed by other ants. In species that forage in groups, a forager that finds food marks a trail on the way back to the colony; this trail is followed by other ants, these ants then reinforce the trail when they head back with food to the colony. When the food source is exhausted, no new trails are marked by returning ants and the scent slowly dissipates. This behaviour helps ants deal with changes in their environment. For instance, when an established path to a food source is blocked by an obstacle, the foragers leave the path to explore new routes. If an ant is successful, it leaves a new trail marking the shortest route on its return. Successful trails are followed by more ants, reinforcing better routes and gradually identifying the best path. Ants use pheromones for more than just making trails. A crushed ant emits an alarm pheromone that sends nearby ants into an attack frenzy and attracts more ants from farther away. Several ant species even use "propaganda pheromones" to confuse enemy ants and make them fight among themselves. Pheromones are produced by a wide range of structures including Dufour's glands, poison glands and glands on the hindgut, pygidium, rectum, sternum, and hind tibia. Pheromones also are exchanged, mixed with food, and passed by trophallaxis, transferring information within the colony.
== Structure == Similar to G protein-coupled receptors (GPCRs), AdipoR2 also possesses 7 transmembrane domains. However, AdipoR2 is orientated oppositely to GPCRs in the membrane (i.e., cytoplasmic N-terminus, extracellular C-terminus) and does not associate with G proteins.
Nervous tissue is composed of many nerve cells known as neurons which transmit information. In some slow-moving radially symmetrical marine animals such as ctenophores and cnidarians (including sea anemones and jellyfish), the nerves form a nerve net, but in most animals they are organized longitudinally into bundles. In simple animals, receptor neurons in the body wall cause a local reaction to a stimulus. In more complex animals, specialized receptor cells such as chemoreceptors and photoreceptors are found in groups and send messages along neural networks to other parts of the organism. Neurons can be connected together in ganglia. In higher animals, specialized receptors are the basis of sense organs and there is a central nervous system (brain and spinal cord) and a peripheral nervous system. The latter consists of sensory nerves that transmit information from sense organs and motor nerves that influence target organs. The peripheral nervous system is divided into the somatic nervous system which conveys sensation and controls voluntary muscle, and the autonomic nervous system which involuntarily controls smooth muscle, certain glands and internal organs, including the stomach.
Specific industries, such as the airline, healthcare and food industries, have special concerns. Due to rising rates of obesity, airlines face higher fuel-costs and pressures to increase seating-width. In 2000, the extra weight of passengers with obesity cost airlines US$275 million. The healthcare industry has invested in special facilities for handling patients with class III obesity, including special lifting equipment and bariatric ambulances. Litigation accusing restaurants of causing obesity increases restaurant costs. In 2005, the US Congress discussed legislation to prevent civil lawsuits against the food industry in relation to obesity; however, it did not become law. With the American Medical Association's 2013 classification of obesity as a chronic disease, it is thought that health-insurance companies will more likely pay for obesity treatment, counseling and surgery, and the cost of research and development of adipose-treatment pills or gene-therapy treatments should become more affordable if insurers help to subsidize their cost. The AMA classification is not legally binding, however, so health insurers still have the right to reject coverage for a treatment or procedure. In 2014, The European Court of Justice ruled that morbid obesity is a disability. The Court said that if an employee's obesity prevents "full and effective participation of that person in professional life on an equal basis with other workers", then it shall be considered a disability and that firing someone on such grounds is discriminatory.
Sources: en.wikipedia.org
== See also == Russell 3000 Index – U.S. all-cap stock market index Russell 1000 Index – U.S. large-cap stock market index S&P 600 – American small-cap stock market index List of largest daily changes in the Russell 2000
As these coils are rapidly switched during the excitation and response to perform a moving line scan, they create the characteristic repetitive noise of an MRI scan as the windings move slightly due to magnetostriction. The contrast between different tissues is determined by the rate at which excited atoms return to the equilibrium state. Exogenous contrast agents may be given to the person to make the image clearer.
Rhodesia had a centralised government and was divided into seven provinces and two cities with provincial status, for administrative purposes. Each province had a provincial capital from where government administration was usually carried out.
==== MeSH D12.776.377.715.548 – immunoglobulins ==== MeSH D12.776.377.715.548.114 – antibodies MeSH D12.776.377.715.548.114.071 – antibodies, anti-idiotypic MeSH D12.776.377.715.548.114.107 – antibodies, archaeal MeSH D12.776.377.715.548.114.125 – antibodies, bacterial MeSH D12.776.377.715.548.114.125.288 – antistreptolysin MeSH D12.776.377.715.548.114.134 – antibodies, bispecific MeSH D12.776.377.715.548.114.143 – antibodies, blocking MeSH D12.776.377.715.548.114.167 – antibodies, catalytic MeSH D12.776.377.715.548.114.179 – antibodies, fungal MeSH D12.776.377.715.548.114.185 – antibodies, helminth MeSH D12.776.377.715.548.114.191 – antibodies, heterophile MeSH D12.776.377.715.548.114.224 – antibodies, monoclonal MeSH D12.776.377.715.548.114.224.570 – muromonab-cd3 MeSH D12.776.377.715.548.114.240 – antibodies, neoplasm MeSH D12.776.377.715.548.114.248 – antibodies, phospho-specific MeSH D12.776.377.715.548.114.252 – antibodies, protozoan MeSH D12.776.377.715.548.114.254 – antibodies, viral MeSH D12.776.377.715.548.114.254.150 – deltaretrovirus antibodies MeSH D12.776.377.715.548.114.254.150.440 – hiv antibodies MeSH D12.776.377.715.548.114.254.150.500 – htlv-i antibodies MeSH D12.776.377.715.548.114.254.150.510 – htlv-ii antibodies MeSH D12.776.377.715.548.114.254.450 – hepatitis antibodies MeSH D12.776.377.715.548.114.254.450.251 – hepatitis a antibodies MeSH D12.776.377.715.548.114.254.450.504 – hepatitis b antibodies MeSH D12.776.377.715.548.114.254.450.510 – hepatitis c antibodies MeSH D12.776.377.715.548.114.257 – antigen-antibody complex MeSH D12.776.377.715.548.114.301 – antitoxins MeSH D12.776.377.715.548.114.301.138 – antivenins MeSH D12.776.377.715.548.114.301.268 – botulinum antitoxin MeSH D12.776.377.715.548.114.301.438 – diphtheria antitoxin MeSH D12.776.377.715.548.114.301.849 – tetanus antitoxin MeSH D12.776.377.715.548.114.323 – autoantibodies MeSH D12.776.377.715.548.114.323.190 – antibodies, antineutrophil cytoplasmic MeSH D12.776.377.715.548.114.323.204 – antibodies, antinuclear MeSH D12.776.377.715.548.114.323.210 – antibodies, antiphospholipid MeSH D12.776.377.715.548.114.323.210.100 – antibodies, anticardiolipin MeSH D12.776.377.715.548.114.323.210.600 – lupus coagulation inhibitor MeSH D12.776.377.715.548.114.323.300 – complement c3 nephritic factor MeSH D12.776.377.715.548.114.323.390 – immunoconglutinins MeSH D12.776.377.715.548.114.323.480 – immunoglobulins, thyroid-stimulating MeSH D12.776.377.715.548.114.323.480.500 – long-acting thyroid stimulator MeSH D12.776.377.715.548.114.323.732 – rheumatoid factor MeSH D12.776.377.715.548.114.345 – binding sites, antibody MeSH D12.776.377.715.548.114.345.180 – complementarity determining regions MeSH D12.776.377.715.548.114.525 – hemolysins MeSH D12.776.377.715.548.114.573 – immune sera MeSH D12.776.377.715.548.114.573.203 – antilymphocyte serum MeSH D12.776.377.715.548.114.580 – immunoconjugates MeSH D12.776.377.715.548.114.580.450 – immunotoxins MeSH D12.776.377.715.548.114.606 – immunoglobulin allotypes MeSH D12.776.377.715.548.114.606.586 – immunoglobulin gm allotypes MeSH D12.776.377.715.548.114.606.587 – immunoglobulin km allotypes MeSH D12.776.377.715.548.114.619 – immunoglobulin isotypes MeSH D12.776.377.715.548.114.619.026 – immunoglobulin a MeSH D12.776.377.715.548.114.619.026.030 – immunoglobulin a, secretory MeSH D12.776.377.715.548.114.619.026.030.500 – secretory component MeSH D12.776.377.715.548.114.619.026.515 – immunoglobulin alpha-chains MeSH D12.776.377.715.548.114.619.251 – immunoglobulin d MeSH D12.776.377.715.548.114.619.251.500 – immunoglobulin delta-chains MeSH D12.776.377.715.548.114.619.312 – immunoglobulin e MeSH D12.776.377.715.548.114.619.312.500 – immunoglobulin epsilon-chains MeSH D12.776.377.715.548.114.619.393 – immunoglobulin g MeSH D12.776.377.715.548.114.619.393.522 – immunoglobulin gamma-chains MeSH D12.776.377.715.548.114.619.393.522.400 – immunoglobulin gm allotypes MeSH D12.776.377.715.548.114.619.393.550 – long-acting thyroid stimulator MeSH D12.776.377.715.548.114.619.393.570 – muromonab-cd3 MeSH D12.776.377.715.548.114.619.393.700 – rho(d) immune globulin MeSH D12.776.377.715.548.114.619.574 – immunoglobulin m MeSH D12.776.377.715.548.114.619.574.500 – immunoglobulin mu-chains MeSH D12.776.377.715.548.114.632 – immunoglobulins, intravenous MeSH D12.776.377.715.548.114.648 – immunoglobulins, thyroid-stimulating MeSH D12.776.377.715.548.114.656 – insulin antibodies MeSH D12.776.377.715.548.114.664 – isoantibodies MeSH D12.776.377.715.548.114.715 – oligoclonal bands MeSH D12.776.377.715.548.114.767 – opsonin proteins MeSH D12.776.377.715.548.114.820 – plantibodies MeSH D12.776.377.715.548.114.837 – precipitins MeSH D12.776.377.715.548.114.890 – reagins MeSH D12.776.377.715.548.397 – gamma-globulins MeSH D12.776.377.715.548.397.500 – tuftsin MeSH D12.776.377.715.548.538 – immunoglobulin constant regions MeSH D12.776.377.715.548.538.249 – immunoglobulin fab fragments MeSH D12.776.377.715.548.538.500 – immunoglobulin fc fragments MeSH D12.776.377.715.548.538.500.249 – cd4 immunoadhesins MeSH D12.776.377.715.548.680 – immunoglobulin fragments MeSH D12.776.377.715.548.680.650 – immunoglobulin fab fragments MeSH D12.776.377.715.548.680.650.500 – immunoglobulin variable region MeSH D12.776.377.715.548.680.650.500.180 – complementarity determining regions MeSH D12.776.377.715.548.680.650.500.590 – immunoglobulin joining region MeSH D12.776.377.715.548.680.650.750 – tuftsin MeSH D12.776.377.715.548.680.660 – immunoglobulin fc fragments MeSH D12.776.377.715.548.680.660.249 – cd4 immunoadhesins MeSH D12.776.377.715.548.680.660.500 – immunoglobulin constant regions MeSH D12.776.377.715.548.680.745 – immunoglobulin idiotypes MeSH D12.776.377.715.548.705 – immunoglobulin subunits MeSH D12.776.377.715.548.705.500 – immunoglobulin heavy chains MeSH D12.776.377.715.548.705.500.350 – immunoglobulin alpha-chains MeSH D12.776.377.715.548.705.500.360 – immunoglobulin delta-chains MeSH D12.776.377.715.548.705.500.370 – immunoglobulin epsilon-chains MeSH D12.776.377.715.548.705.500.380 – immunoglobulin gamma-chains MeSH D12.776.377.715.548.705.500.380.500 – immunoglobulin gm allotypes MeSH D12.776.377.715.548.705.500.500 – immunoglobulin mu-chains MeSH D12.776.377.715.548.705.625 – immunoglobulin j-chains MeSH D12.776.377.715.548.705.750 – immunoglobulin light chains MeSH D12.776.377.715.548.705.750.530 – immunoglobulin kappa-chains MeSH D12.776.377.715.548.705.750.530.500 – immunoglobulin km allotypes MeSH D12.776.377.715.548.705.750.550 – immunoglobulin lambda-chains MeSH D12.776.377.715.548.705.875 – secretory component MeSH D12.776.377.715.548.797 – immunoglobulin variable region MeSH D12.776.377.715.548.797.180 – complementarity determining regions MeSH D12.776.377.715.548.797.570 – immunoglobulin fab fragments MeSH D12.776.377.715.548.797.590 – immunoglobulin joining region MeSH D12.776.377.715.548.900 – paraproteins MeSH D12.776.377.715.548.900.120 – bence jones protein MeSH D12.776.377.715.548.900.225 – cryoglobulins MeSH D12.776.377.715.548.900.500 – myeloma proteins MeSH D12.776.377.715.548.900.700 – pyroglobulins MeSH D12.776.377.715.548.950 – receptors, antigen, b-cell MeSH D12.776.377.715.548.950.500 – antigens, cd79
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
冻融过程中冰晶形成与局部浓度升高会促使肽链发生界面吸附和聚集。聚集不仅降低有效含量，还会改变可见异物与不溶性微粒的计数结果。将溶液分装为单次使用的小体积等份可减少循环次数。